

Panel discussion on COVID-19: How has the RNA industry adapted to beat the pandemic

Smi Reports: The 2021 conference is set to explore the latest developments in RNA delivery agents and RNA-based therapeutics

LONDON, LONDON BRIDGE , UNITED KINGDOM, November 16, 2020 /EINPresswire.com/ -- [RNA therapeutics](#) is a rapidly expanding industry with increasingly growing potential for immunotherapy personalised medicines, and treatment of genetic, infectious and chronic diseases. This is reflected with the value of the global antisense & RNA therapeutics market expected to reach USD 1.81 billion by 2025, growing at a CAGR of 7.5%.



The poster features a blue and green color scheme with a background of various biological structures, including a DNA double helix, a virus-like particle, and a cell. The text on the poster reads: "Smi Presents the 12th Annual Conference...", "10th - 11th February 2021", "RNA Therapeutics", "Virtual conference: Online access only", and "www.therapeutics-rna.com". Below the poster, the text "RNA Therapeutics 2021" is displayed.

Furthermore, the recent advances of AI technology for RNA drug discovery, as well as new strides in the delivery of messenger RNA transcribed in vitro, have triggered a major expansion of the RNA-therapeutics field.

In recent news Pfizer and BioNTech Announce Vaccine Candidate Against [COVID-19](#) Achieved Success in First Interim Analysis from Phase 3 Study*

Our co-chair Heinrich Haas, Vice President Formulation and Drug Delivery, BioNTech RNA Pharmaceuticals will be moderating the panel discussion on:

COVID-19: how has the RNA industry adapted to beat the pandemic

- The global collaboration to facilitate development and evaluation of therapeutics, diagnostics and vaccines against COVID-19
- Current mRNA vaccines in development
- How has industry adapted clinical trials and R&D to allow accelerated development?
- How have approval processes been accelerated and will this affect future approval processes

post-pandemic?

Panelists:

Troels Koch, Founder & CEO, Aqiventa

Michael Mulqueen, VP Business Development, eTheRNA immunotherapies

Priya Karmali, VP, Technology Innovation and Development, Arcturus Therapeutics

Kirsty Wydenbach, Deputy Unit Manager/Senior Medical Assessor, MHRA

View the full agenda and speaker line-up here: www.therapeutics-rna.com/einpr3

Alongside the panel discussion Priya Karmali, VP, Technology Innovation and Development, Arcturus Therapeutics will also be presenting on:

mRNA and developing a COVID-19 vaccine

- An introduction to Arcturus Therapeutics
- mRNA technologies and the therapeutic potential
- An overview of the LUNAR delivery technology
- Case Study: LUNAR-COV1

A conference not to be missed! Register today for only £499. Register online: www.therapeutics-rna.com/einpr3

Proudly sponsored by: Thermo Fisher Scientific & eTheRNA immunotherapies

* <https://www.pfizer.com/news>

--- ENDS ---

Contact Information:

For media enquiries contact Jinna Sidhu on Tel: +44 (0)20 7827 6088 / Email: hsidhu@smi-online.co.uk

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at <http://www.smi-online.co.uk>

Jinna Sidhu
SMi Group
02078276088

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/530805665>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2020 IPD Group, Inc. All Right Reserved.